Carregant...
Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation
Activating KRAS mutations in lung adenocarcinoma are characterized with treatment resistance and poor prognosis. As a small molecule inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase, apatinib has been proven successful in advanced gastric cancer and breast cancer....
Guardat en:
| Publicat a: | Onco Targets Ther |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove Medical Press
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5584919/ https://ncbi.nlm.nih.gov/pubmed/28894382 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S139520 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|